Skip to content

A Multi-center Prospective Cohort Study Based on Peritoneal Dialysis Telemedicine-assisted Platform

A Multi-center Prospective Cohort Study Based on Peritoneal Dialysis Telemedicine-assisted Platform

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03571451
Acronym
PDTAP
Enrollment
7000
Registered
2018-06-27
Start date
2016-06-01
Completion date
2025-12-01
Last updated
2023-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal Dialysis

Keywords

peritoneal dialysis, survival rate, technique survival rate, risk factors, end stage renal disease

Brief summary

Increasing the proportion of patients on peritoneal dialysis (PD) may relieve the financial burden caused by the growing number of patients with end-stage renal disease (ESRD). The investigators are developing a PD database in China using peritoneal dialysis telemedicine-assisted platform (PD TAP). The survival rate and technique survival rate of PD patients, as well as risk factors associated with survival and technique survival will be analyzed through PD TAP.

Detailed description

The growing number of patients with ESRD leads to an increasing medical burden all around the world. Patients on PD have a similar long-term survival rate as patients on hemodialysis, with a much lower cost of medical resources. Therefore, increasing the percentage of patients on PD may relieve the increasing financial burden for the whole society. Of note, technique survival and patient survival in PD still need to be improved. Based on results from multi-center cohort studies, some prognostic factors have been explored and intervened in recent years. However, robust data from large samples on potential predictors pertaining to patients' clinical characteristics, and PD practice on clinical outcomes in the real world is still limited. This phenomenon calls an action on exploring novel risk factors of patient outcome, especially through national-level prospective cohort study. The investigators are developing a national-level PD database by registering all patients receiving PD on PD TAP. The study is underway in 27 hospitals from 14 provinces located at 7 geographical regions (northwest, northeast, north, central, southwest, southeast and south) in China. National samples of PD units are recruited based on the availability of professional PD team who is willing participant and could regularly follow participants. Our study aims to enroll adult 7,000 patients with end stage renal disease receiving PD. Patients-, treatment- and telemedicine-level variables are collected at baseline and thus at 3-month intervals. PD practice surveys are collected at baseline. All-cause mortality and transfer to hemodialysis will be recorded as primary outcomes. Other clinical outcomes including infectious and non-infectious complications would be recorded. Apart from the above objectives, potential collaboration between PDTAP and local or international clinical research could develop ancillary studies with specific aims. Examples of key research and ancillary investigation proposed in PDTAP study are as follows: 1) Long-term effects of telemedicine on clinical outcomes of patients on PD: a propensity matched study, 2) Anemia, erythrocyte-stimulating agents, inflammation and the association with mortality in patients on PD, 3) The management of serum calcium, phosphate, and hyperparathyroidism and its relationship with mortality in patients on PD, 4) The prevalence of hypomagnesemia, and all-cause and cardiovascular mortality in patients on PD, 5) The prevalence, predictors, and outcomes of PD-related peritonitis, 6) Association between hemoglobin levels and serum albumin levels and mortality in diabetic and non-diabetic patients on PD, 7) Glucose absorption (measured as the difference between the amount of glucose in peritoneal dialysate absorbed into the peritoneal cavity in 24h and that measured in the 24h drained effluent) and its association with metabolic syndrome, cardiovascular events, and mortality in patients on PD. The follow-up will be continued until the end of the study.

Interventions

None listed

Sponsors

The Second Hospital of Hebei Medical University
CollaboratorOTHER
Army Medical University, China
CollaboratorOTHER
The First Affiliated Hospital of Zhengzhou University
CollaboratorOTHER
Hebei Medical University Third Hospital
CollaboratorOTHER
Peking University Shenzhen Hospital
CollaboratorOTHER
Handan Central Hospital
CollaboratorOTHER
Beijing Haidian Hospital
CollaboratorOTHER
People's Hospital of Qinghai Province
CollaboratorUNKNOWN
Cangzhou Central Hospital
CollaboratorOTHER
The Second Affiliated Hospital of Harbin Medical University
CollaboratorOTHER
Shengjing Hospital
CollaboratorOTHER
The Second Hospital of Anhui Medical University
CollaboratorOTHER
Peking University People's Hospital
CollaboratorOTHER
The First Affiliated Hospital of BaoTou Medical College
CollaboratorOTHER
The People's Hospital of Chuxiong Yi Autonomous Prefecture
CollaboratorUNKNOWN
Beijing miyun district hospital
CollaboratorUNKNOWN
Second Hospital of Shanxi Medical University
CollaboratorOTHER
People's Hospital of Gansu
CollaboratorUNKNOWN
Pingdingshan first people's Hospital
CollaboratorUNKNOWN
The first people's hospital of Xining
CollaboratorUNKNOWN
The First Hospital of Jilin University
CollaboratorOTHER
Cangzhou People's Hospital
CollaboratorOTHER
Taiyuan central hospital
CollaboratorUNKNOWN
People's hospital of Langfang
CollaboratorUNKNOWN
China Rehabilitation Research Center
CollaboratorOTHER_GOV
Dongzhimen Hospital, Beijing
CollaboratorOTHER
Department of Epidemiology and Biostatistics, School of Public Health, Peking University
CollaboratorUNKNOWN
Department of Statistics, Peking University First Hospital
CollaboratorUNKNOWN
Peking University First Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* End-stage renal disease patients receiving maintenance peritoneal dialysis; * more than 14 years old

Exclusion criteria

* receiving temporary PD due to acute kidney injury * loss to follow up without any outcomes recorded.

Design outcomes

Primary

MeasureTime frameDescription
All-cause death10 yearsAll-cause death refers to the number of patients who died within the anticipated time frame. For example death caused by CVD, systemic infection, malignancies (according to the WHO classification), and protein-energy wasting.
Transfer to hemodialysis10 yearsTransfer to hemodialysis refers to the number of patients who were Transfer to hemodialysis from PD due to any cause within the anticipated time frame. For example, caused by dialysis inadequacy, volume overload, infection-related (peritonitis and exitsite infection), catheter dysfunction (catheter blockage and displacement), ultrafiltration failure, et al.

Secondary

MeasureTime frameDescription
Cardiovascular events10 yearsThe incidence of cardiovascular events during the time frame. For example, caused by congestive heart failure, angina or acute myocardial infarction, cerebrovascular accident, and peripheral arterial events.
Abdominal wall complications10 yearsThe incidence of abdominal wall complications occurred during the time frame, such as peritoneal leaks and hernia.
Peritonitis10 yearsThe incidence of peritoneal dialysis related peritonitis during the time frame. Includes first-episode/multi-episode, refractory, relapsing, repeat, and recurrent, organism-specific, peritonitis-related death or transfer to hemodialysis.
Other causes for terminating PD10 yearsThe incidence of other causes for terminating PD during the time frame. For example, caused by kidney transplantation, burnout, caretaker burnout or absence physical handicap preventing self-care.
others10 yearsThe incidence of other complications during the time frame, such as new-onset diabetes/cancer, and encapsulating peritoneal sclerosis.
Exit-site/tunnel infection10 yearsThe incidence of exit-site/tunnel infection during the time frame. Includes organism-specific, infection-related death or transfer to hemodialysis.

Countries

China

Contacts

Primary ContactJie Dong, MD,Ph.D.
jie.dong@bjmu.edu.cn086-010-83572388
Backup ContactTian-tian Ma, MD
086-010-83572388

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026